Predictions
Bio-Gate AG
Start price
Target price
Perf. (%)
€4.36
13.12.20
13.12.20
-
13.12.21
13.12.21
-5.96%
10.01.21
10.01.21
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Catalyst Pharmaceutical Partners Inc
Start price
Target price
Perf. (%)
€3.06
13.12.20
13.12.20
-
13.12.21
13.12.21
1.50%
11.03.21
11.03.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
NIO Inc. ADR
Start price
Target price
Perf. (%)
€34.20
13.12.20
13.12.20
-
13.12.21
13.12.21
6.14%
11.03.21
11.03.21
Could be worthwhile Investment >10% per year
Hensoldt AG
Start price
Target price
Perf. (%)
€13.99
13.12.20
13.12.20
-
13.12.21
13.12.21
-11.94%
14.12.21
14.12.21
Leading role in innovation
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Washington Prime Group Inc.
Start price
Target price
Perf. (%)
€8.09
13.12.20
13.12.20
€11.70
13.12.21
13.12.21
-16.52%
21.12.20
21.12.20
Differentiated customer and product portfolio
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Fair valuation
Avnet Inc.
Start price
Target price
Perf. (%)
€26.20
13.12.20
13.12.20
-
13.12.21
13.12.21
31.30%
14.12.21
14.12.21
Risky Investment
Nanostr.technol.
Start price
Target price
Perf. (%)
€57.50
13.12.20
13.12.20
-
13.12.21
13.12.21
-41.91%
14.12.21
14.12.21
Risky Investment
Ionis Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€37.79
13.12.20
13.12.20
-
13.12.21
13.12.21
-29.55%
14.12.21
14.12.21
Risky Investment
Xcel Energy Inc.
Start price
Target price
Perf. (%)
€53.50
13.12.20
13.12.20
-
13.12.21
13.12.21
11.29%
14.12.21
14.12.21
Risky Investment
Thor Industries Inc.
Start price
Target price
Perf. (%)
€78.04
13.12.20
13.12.20
€95.00
13.12.21
13.12.21
17.15%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Alexion Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€142.00
13.12.20
13.12.20
€170.00
13.12.21
13.12.21
9.00%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
SLM Solutions Group AG
Start price
Target price
Perf. (%)
€15.50
13.12.20
13.12.20
-
13.12.21
13.12.21
5.42%
14.12.21
14.12.21
overvalued
Revenue decline/stagnation expected
EBIT decline/stagnation expected
United Labels
Start price
Target price
Perf. (%)
€0.92
13.12.20
13.12.20
-
13.12.21
13.12.21
180.43%
14.12.21
14.12.21
Probably not worthwhile Investment
High risks for its business
Growths much slower than the competition
Below average Management
Ming Le Sports AG
Start price
Target price
Perf. (%)
€1.27
13.12.20
13.12.20
€1.00
13.12.21
13.12.21
77.95%
03.04.21
03.04.21
Top 10 in its market
Future proof or reliable business model
Good rating
High risks for its business
Curis Inc.
Start price
Target price
Perf. (%)
€6.35
13.12.20
13.12.20
-
13.12.21
13.12.21
37.01%
16.02.21
16.02.21
Below average Marketposition
Probably not worthwhile Investment
Significant cyclical dependencies
Little known brand
Lexicon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.66
13.12.20
13.12.20
-
13.12.21
13.12.21
143.95%
16.02.21
16.02.21
Probably not worthwhile Investment
Significant cyclical dependencies
Up Fintech Holding Ltd.
Start price
Target price
Perf. (%)
€4.74
13.12.20
13.12.20
€28.00
23.10.24
23.10.24
-18.57%
06.01.22
06.01.22
Cisco Systems Inc.
Start price
Target price
Perf. (%)
€36.70
12.12.20
12.12.20
-
12.12.21
12.12.21
6.27%
15.02.21
15.02.21
Fair valuation
High dividend yield expected
Higher risks for its business
Verrica Pharmaceuticals
Start price
Target price
Perf. (%)
€8.75
12.12.20
12.12.20
-
12.12.21
12.12.21
-2.29%
13.12.21
13.12.21
Probably not worthwhile Investment
Inseego Corp.
Start price
Target price
Perf. (%)
€12.26
12.12.20
12.12.20
-
12.12.21
12.12.21
-54.63%
13.12.21
13.12.21
Probably not worthwhile Investment
PhaseBio Pharmaceuticals Inc
Start price
Target price
Perf. (%)
€3.60
12.12.20
12.12.20
-
12.12.21
12.12.21
-42.22%
13.12.21
13.12.21
Probably not worthwhile Investment